TPG (TPG) is exploring a sale of healthcare software company Lyric that could value the business at about $5 billion, Reuters reported Wednesday, citing unnamed people familiar with the matter.

According to the sources, TPG is working with JPMorgan Chase (JPM) on the potential sale, although there is no guarantee that a deal will be reached.

The report said Lyric generates about $250 million in annual EBITDA, which could support a valuation of about $5 billion at a 20-times multiple. Insurers including UnitedHealth (UNH), CVS (CVS) and Humana (HUM) use Lyric to identify and prevent inaccurate medical claims payments, it added.

TPG, JPMorgan did not immediately respond to MT Newswires' requests for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)